288 related articles for article (PubMed ID: 33668876)
41. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
42. Successful treatment of second-time CAR-T 19 therapy after failure of first-time CAR-T 19 and ibrutinib therapy in relapsed mantle cell lymphoma.
Mu J; Liu M; Wang J; Meng J; Zhang R; Jiang Y; Deng Q
Adv Clin Exp Med; 2022 Mar; 31(3):327-335. PubMed ID: 35148570
[TBL] [Abstract][Full Text] [Related]
43. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
[TBL] [Abstract][Full Text] [Related]
44. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.
Li CJ; Jiang C; Liu Y; Bell T; Ma W; Ye Y; Huang S; Guo H; Zhang H; Wang L; Wang J; Nomie K; Zhang L; Wang M
Mol Cancer Ther; 2019 Feb; 18(2):267-277. PubMed ID: 30413649
[TBL] [Abstract][Full Text] [Related]
45. Does Ibrutinib impact outcomes of viral infection by SARS-CoV-2 in mantle cell lymphoma patients?
Alsuliman T; Faict S; Malard F; Genthon A; Brissot E; Van de Wyngaert Z; Ikhlef S; Banet A; Lapusan S; Sestili S; Corre E; M'hammedi-Bouzina F; Schaeffer L; Legrand O; Dulery R; Mohty M; Marjanovic Z
Curr Res Transl Med; 2021 Jan; 69(1):103273. PubMed ID: 33460953
[No Abstract] [Full Text] [Related]
46. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
Jain P; Kanagal-Shamanna R; Zhang S; Ahmed M; Ghorab A; Zhang L; Ok CY; Li S; Hagemeister F; Zeng D; Gong T; Chen W; Badillo M; Nomie K; Fayad L; Medeiros LJ; Neelapu S; Fowler N; Romaguera J; Champlin R; Wang L; Wang ML
Br J Haematol; 2018 Nov; 183(4):578-587. PubMed ID: 30175400
[TBL] [Abstract][Full Text] [Related]
47. CD52 and OXPHOS-potential targets in ibrutinib-treated mantle cell lymphoma.
Fuhr V; Heidenreich S; Srivastava M; Riedel A; Düll J; Gerhard-Hartmann E; Rosenwald A; Rauert-Wunderlich H
Cell Death Discov; 2022 Dec; 8(1):505. PubMed ID: 36587029
[TBL] [Abstract][Full Text] [Related]
48. Zanubrutinib: a new BTK inhibitor for treatment of relapsed/refractory mantle cell lymphoma.
Weaver AN; Jimeno A
Drugs Today (Barc); 2020 Aug; 56(8):531-539. PubMed ID: 33025948
[TBL] [Abstract][Full Text] [Related]
49. Ibrutinib for mantle cell lymphoma.
Tucker DL; Rule SA
Future Oncol; 2016 Feb; 12(4):477-91. PubMed ID: 26759179
[TBL] [Abstract][Full Text] [Related]
50. Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.
Hagner PR; Chiu H; Ortiz M; Apollonio B; Wang M; Couto S; Waldman MF; Flynt E; Ramsay AG; Trotter M; Gandhi AK; Chopra R; Thakurta A
Br J Haematol; 2017 Nov; 179(3):399-409. PubMed ID: 28771673
[TBL] [Abstract][Full Text] [Related]
51. Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma.
Zhang S; Jiang VC; Han G; Hao D; Lian J; Liu Y; Zhang R; McIntosh J; Wang R; Dang M; Dai E; Wang Y; Santos D; Badillo M; Leeming A; Chen Z; Hartig K; Bigcal J; Zhou J; Kanagal-Shamanna R; Ok CY; Lee H; Steiner RE; Zhang J; Song X; Nair R; Ahmed S; Rodriquez A; Thirumurthi S; Jain P; Wagner-Bartak N; Hill H; Nomie K; Flowers C; Futreal A; Wang L; Wang M
Nat Commun; 2021 May; 12(1):2877. PubMed ID: 34001881
[TBL] [Abstract][Full Text] [Related]
52. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
[TBL] [Abstract][Full Text] [Related]
53. SHINE a light: frontline ibrutinib for MCL.
Killock D
Nat Rev Clin Oncol; 2022 Aug; 19(8):494. PubMed ID: 35750854
[No Abstract] [Full Text] [Related]
54. New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
Rule S; Chen RW
Expert Rev Hematol; 2018 Sep; 11(9):749-756. PubMed ID: 30052472
[TBL] [Abstract][Full Text] [Related]
55. Successful Long-Term Ibrutinib Treatment in a Hemodialysis Patient With Leukemic Nonnodal Mantle Cell Lymphoma.
Yasuda H; Tsukune Y; Inano T; Mori Y; Ota Y; Komatsu N
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e176-e178. PubMed ID: 33127325
[No Abstract] [Full Text] [Related]
56. Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.
Freeman CL; Pararajalingam P; Jin L; Balasubramanian S; Jiang A; Xu W; Grau M; Zapukhlyak M; Boyle M; Hodkinson B; Schaffer M; Enny C; Deshpande S; Sun S; Vermeulen J; Morin RD; Scott DW; Lenz G
Leukemia; 2022 Oct; 36(10):2479-2487. PubMed ID: 35963941
[TBL] [Abstract][Full Text] [Related]
57. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
[TBL] [Abstract][Full Text] [Related]
58. Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
Bond DA; Alinari L; Maddocks K
Clin Adv Hematol Oncol; 2019 Apr; 17(4):223-233. PubMed ID: 31188814
[TBL] [Abstract][Full Text] [Related]
59. Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro.
Liu M; Wang X; Li Z; Zhang R; Mu J; Jiang Y; Deng Q; Sun L
Cancer Sci; 2020 Nov; 111(11):4051-4060. PubMed ID: 32876369
[TBL] [Abstract][Full Text] [Related]
60. Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
Molica S; Gianfelici V; Levato L
Expert Opin Emerg Drugs; 2020 Mar; 25(1):25-35. PubMed ID: 31996046
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]